Denali Therapeutics Inc.
DNLINASDAQHealthcare● Active
$19.54
+$0.02(+0.10%)
Market Cap$3.1B
P/E Ratio—
52W High$23.77
52W Low$12.58
Denali Therapeutics Inc. (DNLI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DNLI · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.33B | $0.11B | $0.05B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.01B) | $0.00B | $0.33B | $0.11B | $0.05B |
| Gross Margin %(computed) | — | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.42B | $0.40B | $0.42B | $0.36B | $0.27B |
| G&A Expenses | $0.10B | $0.11B | $0.10B | $0.09B | $0.08B |
| Total Operating Expenses | $0.54B | $0.49B | $0.53B | $0.45B | $0.34B |
| Operating Income | ($0.56B) | ($0.49B) | ($0.20B) | ($0.34B) | ($0.30B) |
| Operating Margin %(computed) | — | — | -59.51% | -314.16% | -607.78% |
| Interest Income | $0.04B | $0.06B | $0.05B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.51B) | ($0.42B) | ($0.15B) | ($0.33B) | ($0.29B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Net Income | ($0.51B) | ($0.42B) | ($0.15B) | ($0.33B) | ($0.29B) |
| Net Margin %(computed) | — | — | -43.94% | -300.56% | -597.15% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
| Wtd Avg Shares | 0.18B | 0.16B | 0.14B | 0.13B | 0.12B |
| EBITDA | ($0.50B) | ($0.49B) | ($0.18B) | ($0.33B) | ($0.29B) |
| EBITDA Margin %(computed) | — | — | -54.45% | -304.58% | -590.12% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Denali Therapeutics Inc. data
About Denali Therapeutics Inc. (DNLI) Income Statement
Denali Therapeutics Inc. (DNLI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DNLI reported revenue of $0.00B, gross profit of ($0.01B) (gross margin —), and net income of ($0.51B) — a net profit margin of —.
Frequently asked questions
DNLI · 4 questionsDenali Therapeutics Inc. (DNLI) reported revenue of $0.00B for 2025, down —% year-over-year.
DNLI revenueDNLI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08